Market Cap: $8M
MI
MetaVia Inc.
MTVA
NASDAQ (NASDAQ Global Market)USD
Market Cap: $8M
MetaVia Inc. (Ticker: MTVA), a clinical-stage biotechnology company based in Cambridge, Massachusetts, focuses on advancing innovative therapies aimed at combating cardiometabolic diseases. Innovative…
MetaVia Inc. (Ticker: MTVA) makes headway in the pharmaceutical industry with its promising drug vanoglipel, which shows potential in treating liver fibrosis and obesity. The company has recently publ…
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…
MetaVia Inc. (Nasdaq: MTVA), a biotechnology company specializing in cardiometabolic diseases, announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726. This dual…
MetaVia Strengthens Intellectual Property Position to Advance Cardiometabolic Solutions MetaVia Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, announces the expansion…
MetaVia Strengthens Position Against Cardiometabolic Diseases with Patent Portfolio MetaVia Inc., a clinical-stage biotechnology company located in Cambridge, Massachusetts, focuses on innovative solu…
MetaVia Strengthens Intellectual Property in Targeting Metabolic Diseases MetaVia Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, highlights its substantial progress wi…
MetaVia Focuses on Innovative Therapies to Tackle Cardiometabolic Diseases MetaVia Inc., a clinical-stage biotechnology firm based in Cambridge, Massachusetts, is at the forefront of developing ground…
Cambridge biotech schedules data briefing ahead of Emerging Growth Conference MetaVia Inc. says its chief executive and chief financial officer will present an update on the company’s obesity and meta…
MetaVia tightens IP protection around long‑acting oxyntomodulin candidate DA‑1726 MetaVia Inc. secures an exclusive global intellectual property portfolio that it says underpins commercialization and…
MetaVia Secures Funding for Cardiometabolic Research MetaVia Inc., a clinical-stage biotechnology company focused on addressing cardiometabolic diseases, successfully completes its underwritten public…
MetaVia Secures Funding for Cardiometabolic Innovations MetaVia Inc., a biotechnology firm located in Cambridge, Massachusetts, focuses on addressing cardiometabolic diseases. The company recently ann…
MetaVia Secures Funding to Advance Obesity Treatment Development MetaVia Inc., a biotechnology company focusing on innovative solutions for cardiometabolic diseases, announces a pivotal step in its de…
MetaVia's Promising Breakthrough in Obesity Treatment: DA-1726 Clinical Trial Results MetaVia Inc. announces encouraging results from its Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin…
MetaVia Achieves Breakthrough Results in Obesity Treatment with DA-1726 MetaVia Inc. announces significant advancements in the treatment of obesity through its Phase 1 clinical trial of DA-1726, a dua…
MetaVia Inc. Reaffirms Commitment to Cardiometabolic Health Solutions MetaVia Inc., a clinical-stage biotechnology company specializing in the treatment of cardiometabolic diseases, announces signific…
MetaVia's Compliance Regained: A Step Forward in Cardiometabolic Innovation MetaVia Inc., a clinical-stage biotechnology company specializing in the treatment of cardiometabolic diseases, announces a…
MetaVia Inc. Implements Reverse Stock Split to Maintain Nasdaq Listing MetaVia Inc. announces a strategic move aimed at ensuring its compliance with Nasdaq's listing requirements by implementing a 1-f…
NeuroBo Pharmaceuticals Advances in Cardiometabolic Treatment Development NeuroBo Pharmaceuticals, a clinical-stage biotech company, focuses on advancing therapies for cardiometabolic diseases. Amidst…
NeuroBo Pharmaceuticals: Pioneering Advances in Therapeutic Solutions NeuroBo Pharmaceuticals focuses on developing innovative therapies targeting neurodegenerative diseases, with a particular emphasi…
NeuroBo Pharmaceuticals: Pioneering Innovation in Healthcare Solutions NeuroBo Pharmaceuticals stands at the forefront of innovative healthcare solutions, focusing on developing therapies for neurodeg…
Novel Therapy Shows Promise in Combatting Metabolic Dysfunction-Associated Steatohepatitis MetaVia Inc. announces significant findings from its Phase 2a clinical trial of vanoglipel (DA-1241), a selec…
MetaVia Inc. Advances Treatment for Metabolic Dysfunction with Vanoglipel MetaVia Inc. announces significant progress in its clinical development of vanoglipel (DA-1241), a selective G protein-coupled…